Abstract
Immune checkpoint inhibitors may have different clinical effects compared with conventional anticancer drugs. An 85-year-old male received chemotherapy for recurrent gastric cancer. As liver metastasis progressed, nivolumab was introduced as a fourth line treatment. Progression of liver metastasis in size was observed in CT after 3 courses of nivolumab therapy. Nivolumab treatment was discontinued, because the general condition of the patient also worsened. However, his general condition improved as hepatobiliary enzyme levels, inflammatory response, and tumor markers improved. Liver metastasis was shrinking on the image, so we resumed nivolumab therapy. To the authors’ knowledge, this is the first case of pseudoprogression undergoing immunotherapy for gastric cancer. In this case, the antitumor effect was exhibited in a delayed manner and the tumor shrinkage was obtained.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461–71.
Chiou VL, BurottoM. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol. 2015;33:3541–3.
Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412–20.
Ozaki Y, Shindoh J, Miura Y, et al. Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report. BMC Cancer. 2017;17:778–84.
Hodi FS, Sznol M, Kluger HM, et al. Long term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treatment with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase 1 trial. J Clin Oncol. 2014;32:supple 15 s (abstr9002).
Kumagai T, Kimura M, Inoue T, et al. Pseudoprogression of lung adenocarcinoma accompanied with interstitial lung disease during chemotherapy after nivolumab treatment. Thoracic Cancer. 2017;8:275–7.
Safarty M, Moore A, Dudnik E, et al. Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab. Medicine. 2017;96:4(e5951).
Lemery S, Keegan P, Pazdur R. First FDA approval agnostic of cancer site—when a biomarker defines the indication. N Engl J Med. 2017;377:1409–12.
Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–20.
Jin Z, Yoon HH. The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1. J Gastrointest Oncol. 2016;7;771–81.
Tran PN, Sarkissian S, Chao J, et al. PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence. Gastrointest Cancer. 2017;7:1–11.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors declare that they have no conflict of interest.
Human/animal rights
All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
Informed consent
Informed consent was obtained from all patients for being included in the study.
Rights and permissions
About this article
Cite this article
Satoyoshi, R., Muto, O., Masuda, A. et al. A case of gastric cancer with delayed onset of tumor reduction effect by nivolumab therapy. Clin J Gastroenterol 12, 15–19 (2019). https://doi.org/10.1007/s12328-018-0902-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12328-018-0902-0